Drug Approval | June 10, 2022
Sanofi Dupixent gets USFDA nod for atopic dermatitis
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Healthcare is timely and personal – and its delivery should be too
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
Based on a post hoc analysis, fewer required respiratory interventions
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team.
States have an important role in ensuring food safety and healthy food practices.
This MoU will further strengthen relations between India and the USA within the framework of international scientific and technological cooperation in fields of mutual interest.
CerTest Biotec uses the BD MAX molecular diagnostic system open system reagent suite to develop RT-PCR detection kit
The Innopack confex is a perfect platform for exhibitors to demonstrate their latest developments in the fields of pharmaceutical packaging, labelling, drug delivery device design and engineering.
Subscribe To Our Newsletter & Stay Updated
